CALT News and Press, Calliditas Therapeutics AB From 11/30/23

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome PR Newswire STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced the initiation of a Ph...

2023-11-27 18:40:01 ET Summary Q3 2023 sales for Calliditas Therapeutics' flagship drug Tarpeyo fell short of expectations but showed incremental growth. Despite challenges, the number of prescribers and improvements in market access for Tarpeyo indicate long-term success. 202...

2023-11-27 17:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-24 08:00:38 ET More on Calliditas Therapeutics Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point Calliditas stock dips as losses widen in Q3 Seeking Alpha’s Quant Rating on Calliditas Therapeutics Historica...

Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy PR Newswire STOCKHOLM , Nov. 24, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ...

Calliditas Therapeutics AB (CALT) is expected to report $-0.22 for Q3 2023

Calliditas to present at upcoming investor conferences PR Newswire STOCKHOLM , Nov. 7, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the ...

Calliditas Interim Report January - September 2023 PR Newswire STOCKHOLM , Nov. 7, 2023 /PRNewswire/ -- The Lancet publication of full Phase 3 data set In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published i...

Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023 PR Newswire STOCKHOLM , Nov. 6, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("C...

New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy PR Newswire STOCKHOLM , Oct. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm...